Show simple item record

dc.contributor.authorPerri, M.
dc.contributor.authorYap, J.L.
dc.contributor.authorFletcher, S.
dc.date.accessioned2019-05-17T12:53:04Z
dc.date.available2019-05-17T12:53:04Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85044638957&doi=10.3892%2fol.2018.8258&partnerID=40&md5=66e1ae13d1b6a4efec2eebc22338c15c
dc.identifier.urihttp://hdl.handle.net/10713/9081
dc.description.abstractOverexpression of anti-apoptotic proteins belonging to the B cell lymphoma (Bcl)-2 family is observed in numerous cancer types and has been postulated to promote cancer cell survival and chemotherapy resistance. Bcl-extra large (xL)/myeloid cell leukemia sequence (Mcl)-1 was demonstrated to be expressed at relatively high levels in clinically aggressive basal-like cancers and inhibiting Bcl-xL overexpression could potentially provoke cell death. A molecule able to target Bcl-xL/Mcl-1, JY-1-106, is herein under investigation. It is also known that vitamin A-derived compounds exhibit antitumor activity in a variety of in vitro experimental models, promoting their effects via nuclear receptor isoforms including retinoic acid receptors (RARs). Pre-clinical observation highlighted that triple negative (estrogen receptor/progesterone receptor/human epidermal growth factor receptor)-breast cancer cells displayed resistance to retinoids due to the RARγ high expression profile. The present study used the triple-negative human breast cancer cell line, MDA-MB-231, to analyze the effects of the Bcl-xL/Mcl-1 synthetic inhibitor, JY-1-106, alone or in combination with retinoids on cell viability. The results revealed a synergistic effect in reducing cell viability primarily by using JY-1-106 with the selective RAR? antagonist SR11253, which induces massive autophagy and necrosis. Furthermore, the results highlighted that JY-1-106 alone is able to positively influence the gene expression profile of p53 and RARγ , providing a therapeutic advantage in human triple-negative breast cancer treatment. Copyright 2018, Spandidos Publications. All rights reserved.en_US
dc.description.sponsorshipThis work was supported by Regional Operative Programme (ROP) Calabria ESF 2007/2013-IV Axis Human Capital-Operative Objective M2-Action d.5 Postdoctoral Fellowship, in collaboration with University of Calabria (Cs), Italy to M.P.. Thanks to this, M.P. was able to work in Kane's Lab and to collaborate with Dr Fletcher at University of Maryland, School of Pharmacy.en_US
dc.description.urihttps://dx.doi.org/10.3892/ol.2018.8258en_US
dc.language.isoen_USen_US
dc.publisherSpandidos Publicationsen_US
dc.relation.ispartofOncology Letters
dc.subjectAutophagyen_US
dc.subjectMDA-MB-231 breast cancer cells, Bcl-xL/Mcl-1 inhibitoren_US
dc.subjectRARγ antagonisten_US
dc.subjectRetinoidsen_US
dc.titleTherapeutic potential of bcl-xl/mcl-1 synthetic inhibitor jy-1-106 and retinoids for human triple-negative breast cancer treatmenten_US
dc.typeArticleen_US
dc.identifier.doi10.3892/ol.2018.8258


This item appears in the following Collection(s)

Show simple item record